08:54 AM EDT, 04/10/2025 (MT Newswires) -- Oculis Holding ( OCS ) said Thursday that it has completed enrollment in two late-stage trials of OCS-01 eye drops in diabetic macular edema.

The trials, which enrolled more than 800 patients from the US and other countries, will assess the eye drops' efficacy and safety after 52 weeks of treatment, the company said.

The company said topline data from both trials is expected in Q2 of next year, followed by the submission of a new drug application.

Oculis shares were up 5.7% in recent premarket activity Thursday.